3-tert-Butyl-4H-benzo[1,2,4]thiadiazine 1,1-dioxide | 37162-61-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻二嗪
• 英文名称: 3-tert-Butyl-4H-benzo[1,2,4]thiadiazine 1,1-dioxide
• 英文别名: 3-Tert-butyl-4H-1lambda6,2,4-benzothiadiazine 1,1-dioxide；3-tert-butyl-4H-1λ6,2,4-benzothiadiazine 1,1-dioxide
• CAS: 37162-61-1
• 化学式: C₁₁H₁₄N₂O₂S
• 分子量: 238.31
• InChiKey: IGCKEPXNGVXICF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  66.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  邻氨基苯磺酰胺 、 三甲基乙酸 在 polyphosphoric acid trimethylsilyl ester 作用下， 反应 2.0h， 以52%的产率得到3-tert-Butyl-4H-benzo[1,2,4]thiadiazine 1,1-dioxide
  参考文献：
  名称：

  A Convenient Synthesis of 2H-1,2,4-Benzothiadiazine 1,1-Dioxides from 2-Aminobenzenesulfonamide and Carboxylic Acids by using Polyphosphoric Acid Trimethylsilyl Ester as Condensing Agent

  摘要：

  DOI：

  10.1055/s-1983-30543

文献信息

• Bridged Ring compounds As Hepatitis C Virus (HCV) Inhibitors And Pharmaceutical Applications Thereof
  申请人：SUNSHINE LAKE PHARMA CO., LTD

  公开号：US20150079028A1

  公开（公告）日：2015-03-19

  Provided herein is a compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, which can be used for treating HCV infection or a HCV disorder.

  提供了一种具有公式(I)的化合物，或其立体异构体、几何异构体、互变异构体、N-氧化物、水合物、溶剂化物、代谢物、药用盐或前药，可用于治疗HCV感染或HCV疾病。还提供了包含本处所述化合物的药物组合物，可用于治疗HCV感染或HCV疾病。
• IMAI, Y.;MOCHIZUKI, A.;KAKIMOTO, M., SYNTHESIS, BRD, 1983, N 10, 851
  作者：IMAI, Y.、MOCHIZUKI, A.、KAKIMOTO, M.

  DOI：——

  日期：——
• SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS
  申请人：SUNSHINE LAKE PHARMA CO., LTD.

  公开号：US20150232509A1

  公开（公告）日：2015-08-20

  A compound of formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof is provided, which can be used for treating HCV infection or a HCV disorder. Also a pharmaceutical composition comprising the compound and the use of the compound and the pharmaceutical composition thereof are provided, which can also be used for treating HCV infection or a HCV disorder.
• SPIRO RING COMPOUND AS HEPATITIS C VIRUS (HCV) INHIBITOR AND USES THEREOF
  申请人：SUNSHINE LAKE PHARMA CO., LTD.

  公开号：US20150299215A1

  公开（公告）日：2015-10-22

  A compound of formula (I) or a stereoisomer, a geometric isomer. a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof is provided, which can be used for treating HCV infection or a HCV disorder. Also a pharmaceutical composition comprising the compound and the use of the compound and the pharmaceutical composition thereof are provided, which can also be used for treating HCV infection or a HCV disorder.
• FUSED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
  申请人：SUNSHINE LAKE PHARMA CO., LTD.

  公开号：US20150307509A1

  公开（公告）日：2015-10-29

  Provided are fused tricyclic compounds effective to inhibit the function of the NS5A protein of formula (I), wherein X, X′, Y, Y′, A, A′, Q 1 , Q 2 , R 1 -R 4 , X 4 , R 5a , f and W are defined as in the description. Also provided herein are pharmaceutical compositions thereof, and uses in the manufacture of a medicament for treating HCV infection or a HCV disorder thereof.